Acumen Pharmaceuticals (ABOS) Receivables - Accured (2023 - 2024)
Acumen Pharmaceuticals (ABOS) reported Receivables - Accured of $53000.0 for Q4 2024, down 76.44% on a YoY basis from $225000.0 in Q1 2024, and down 76.44% sequentially from $225000.0 in Q4 2023.
Acumen Pharmaceuticals (ABOS) Receivables - Accured (2023 - 2024) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 2 years of Receivables - Accured data on file, last reported at $53000.0 in Q4 2024.
- For the quarter ending Q4 2024, Receivables - Accured fell 76.44% year-over-year to $53000.0; the trailing twelve-month figure through Dec 2024 stood at $53000.0 (down 76.44% YoY), and the FY2024 full-year result was $53000.0, down 76.44% from the prior year.
- Receivables - Accured retreated to $53000.0 in Q4 2024, from $225000.0 in the prior quarter.
- In the past five years, Receivables - Accured ranged from a high of $225000.0 in Q4 2023 to a low of $53000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | - |
| 10 | Acumen Pharmaceuticals | 141.30 Mn | 141.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2023 | 225,000.00 |
| Dec 31, 2023 | 225,000.00 |